Categorynews

Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer

May 7, 2019 Off By BusinessWire

LONDON–(BUSINESS WIRE)–Engitix Ltd, a company pioneering the development of both
tissue-specific and disease-specific human extracellular matrix (ECM)
for accelerating and improving the drug discovery process, today
announces the appointment of Gino Van Heeke, PhD, as Chief Scientific
Officer (CSO), effective 7^th May.

Dr Van Heeke has over 20 years of experience and success in both
biologics and small molecule drug discovery and development. He joins
Engitix from Ablynx, where he spent five years as Senior Director,
Discovery and Early Development. During his tenure, he was responsible
for a portfolio of more than 30 proprietary and partnered drug discovery
projects. Before this, he held a series of senior positions at Novartis,
latterly as Executive Director in the Respiratory Diseases Therapeutic
Area.

Dr Giuseppe Mazza, Co-Founder and CEO of Engitix Ltd, said: “We
are extremely pleased to welcome Dr Van Heeke as our Chief Scientific
Officer at such an exciting time at Engitix. He is a results-driven
scientist with extensive translational research expertise covering all
aspects from target discovery and validation through to pre-clinical
development and clinical proof-of-concept of drug candidates. His
expertise will no doubt prove invaluable and, together with our unique
human ECM drug discovery platform in fibrosis and solid tumours, will
drive the successful translation of Engitix’s new drug targets into
pre-clinical and clinical development”.

Commenting on his appointment as CSO, Dr Van Heeke, said: “I’m
delighted to join Engitix and its team of talented scientists, at an
exciting stage of the company’s development and look forward to helping
Engitix deliver on its ambition to develop new therapeutic options for
patients with advanced chronic liver diseases and solid tumours”.

Background on Dr Van Heeke

Dr Van Heeke began his career as a Research Scientist at Restoragen, a
US start-up focused on recombinant peptides. From there, and after three
years as an academic at the Interdisciplinary Center for Biotechnology
Research at the University of Florida, he joined Ciba Pharmaceuticals
where he led a research group focused on the production of
biopharmaceuticals and protein tools for drug discovery. He subsequently
moved to Novartis, UK, helping to develop Novartis’ respiratory
franchise over a 19 year period during which he held positions of
increasing seniority. Throughout his career, Dr Van Heeke has initiated,
led and managed portfolios of programmes in immunology and oncology that
have resulted in the transition of multiple candidate drugs from
research into clinical development and the delivery of successful
clinical ‘Proof of Concept’ studies.

He holds a B.Eng. in Biochemical Engineering and a PhD in Biochemistry
and Molecular Biology.

-ENDS-

About Engitix Ltd

Engitix was established in 2016 to develop and commercialise research at
the UCL Institute for Liver and Digestive Health, Division of Medicine.
The Company was founded by Professor Massimo Pinzani and Dr Giuseppe
Mazza and owns the first platform in the world based on tissue-specific
and disease-specific human extracellular matrix scaffolds. Engitix is
based at the Royal Free Hospital in London, UK.

For more information, please visit www.engitix.com